• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Reviews in medical virology >Simian virus 40 (SV40) and human cancer: a review of the serological data.
【24h】

Simian virus 40 (SV40) and human cancer: a review of the serological data.

机译：猿猴病毒40（SV40）与人类癌症：血清学数据综述。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Serum antibodies are widely utilised as specific and sensitive markers of virus infections but they have been employed relatively infrequently in the investigation of simian virus 40 (SV40) as a human carcinogen. In the past few years, serological data have become available which allow an examination of whether SV40 is currently circulating in human communities and if SV40 infection is associated with human cancer. The development of EIA with virus-like particles (VLPs) of SV40, BKV and JCV has facilitated serological studies. Sera from macaques naturally infected with SV40 cross-react unambiguously with BKV and JCV VLPs. Tests of over 9000 human sera with different immunological assays reveal a common pattern of SV40 reactivity. A small proportion of sera react at low titers and this reactivity is unrelated to age or the geographic location of the donor, but correlates with the presence and titers of BKV and JCV antibodies. Absorption with BKV and JCV VLPs decreases or abolishes the SV40 reactivity ofhuman sera. The SV40 reactivity of sera from patients with mesothelioma, osteosarcoma or lymphomas, cancers which are reported to be associated with SV40, was similar to that in their controls or other comparison groups. The SV40 reactivity of human sera appears to be almost entirely a result of cross-reactivity with BKV and JCV antibodies. Serological data thus do not support the possibility that SV40 is circulating in human communities or that it is associated with human cancer.
机译：血清抗体被广泛用作病毒感染的特异性和敏感标记，但是在猿猴病毒40（SV40）作为人类致癌物的研究中，血清抗体相对较少地被使用。在过去的几年中，已经获得了血清学数据，可用于检查SV40是否正在人类社区中流通以及SV40感染是否与人类癌症有关。带有SV40，BKV和JCV病毒样颗粒（VLP）的EIA的开发促进了血清学研究。天然感染SV40的猕猴的血清与BKV和JCV VLP明确发生交叉反应。使用不同的免疫学方法对9000多种人血清进行的测试揭示了SV40反应性的常见模式。一小部分血清以低滴度反应，这种反应性与供体的年龄或地理位置无关，但与BKV和JCV抗体的存在和滴度相关。 BKV和JCV VLP的吸收减少或消除了人血清的SV40反应性。间皮瘤，骨肉瘤或淋巴瘤（据报道与SV40相关的癌症）患者血清的SV40反应性与对照组或其他比较组相似。人血清的SV40反应性似乎几乎完全是与BKV和JCV抗体交叉反应的结果。因此，血清学数据不支持SV40在人类社区中传播或与人类癌症相关的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号